Bivalirudin in percutaneous coronary intervention
نویسندگان
چکیده
منابع مشابه
Bivalirudin in percutaneous coronary intervention
Bivalirudin is a member of the direct thrombin inhibitor group of anticoagulants. It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins in the settings of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). Results of clinical trials to date suggest bivalirudin is a viable alternative to the use of a heparin combined with a glycoprot...
متن کاملImproving outcomes with bivalirudin in primary percutaneous coronary intervention.
Optimal pharmacotherapy is essential to realize the bestoutcomes in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). In this regard, effectively restoring reperfusion and maintaining the patency of the infarct artery after stenting requires a balance between the haemorrhagic risks and the ischaemic benefits of anticoagu...
متن کاملThe role of bivalirudin in percutaneous coronary intervention.
Bivalirudin (angiomax) is a reversible direct thrombin inhibitor. It is a polypeptide that has a carboxy-terminal region that recognizes thrombin’s fibrinogen-binding site, and an amino-terminal tetrapeptide that inhibits the active site of thrombin. It is considered superior to its prototype; hirudin as it is less dependent on renal function and has a lower incidence of anaphylaxis. Bivalirudi...
متن کاملPercutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
Previously, indirect thrombin inhibitors such as unfractionated heparin or low-molecular-weight heparin were used as a standard anticoagulation during percutaneous coronary intervention to prevent procedural thrombotic complications but at a risk of hemorrhagic complications. More recently, bivalirudin, a member of the direct thrombin inhibitor class, has been shown to have 1) predictable pharm...
متن کاملDynamic changes in purine catabolism in patients with acute coronary syndrome that underwent percutaneous coronary intervention
Background: Cardiovascular diseases are global problems. They are causes of death in about 43% of people worldwide and may become the most widespread reason of death by 2020. The prognosis is directly dependent to immediate diagnosis and on time treatment. Introduction of new biochemical markers as the early diagnosis of complications after coronary revascularization is very important in this p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vascular Health and Risk Management
سال: 2006
ISSN: 1176-6344
DOI: 10.2147/vhrm.2006.2.4.357